A prescription alone cannot establish an applicable compounding exemption. The current 503A regulation and interim records do not establish ordinary retail bulk eligibility; clinical investigation has separate authorization requirements [11].
Ordinary retail eligibility is not established
A drug reaches a patient lawfully in one of a few ways. It is approved by FDA, compounded by a licensed pharmacy from an allowed ingredient, or accessed through an applicable, properly authorized investigational pathway [1]. A registry listing does not itself establish that authorization. MOTS-c fails the first two. The table shows each route.
| Route | Available for MOTS-c? | Why |
|---|---|---|
| FDA-approved drug | No | No MOTS-c drug has ever been approved [3] |
| 503A compounding pharmacy | No | No monograph, not part of an approved drug, not on the bulks list, in no category [5] |
| 503B outsourcing facility | No | The reviewed 503B nomination categories do not list MOTS-c. This nomination document is not the final bulks regulation or a complete statement of legal requirements [6] |
| "Research use only" vials | Not for human use | Not approved drugs; FDA treats this label on other peptides as no defense [7] |
| Investigational study | Only with applicable authorization and eligibility | One phase 2 trial is registered, at a site in China [8] |
Sources: FDA briefing (July 2026), FDA 503A list (May 14, 2026), FDA 503B list (March 21, 2025), ClinicalTrials.gov.
A prescription does not establish a compounding exemption
A 503A pharmacy may compound from a raw ingredient only if the ingredient has a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list [4]. FDA's briefing closes the first two doors in a single sentence:
There is no applicable United States Pharmacopeia (USP) or National Formulary (NF) drug substance monograph for MOTS-c (free base) or its acetate form, and neither is a component of an FDA-approved drug.[3]
The third door, the bulks list, is the one FDA's committee discussed in July. MOTS-c isn't on it. Nor is it in Category 1, the group FDA lets pharmacies use while it decides [5]. A prescription from a doctor doesn't change any of this. The pharmacy still needs a lawful ingredient to fill it.
FDA’s current safety page places MOTS-c among withdrawn nominations. That change is not a finding of safety or an approval. Historical archive-date claims are omitted here unless the exact original document is established.
"Research use only" is a label, not a permission
Online MOTS-c offers may carry a "research use only" or "not for human consumption" label. It's a disclaimer. It doesn't turn a peptide sold to the public into a lawful product. FDA has warned companies selling unapproved GLP-1-type peptides "falsely labeled" that way, saying the products were sold directly to consumers for human use with dosing instructions [7].
Those warnings name semaglutide, tirzepatide, retatrutide and similar drugs, not MOTS-c. The principle is the same, though: what a seller says on its site counts, not just what the vial says. The same storefronts sell BPC-157, and why none of them is a legal source is set out in whether you can buy BPC-157 legally.
FDA identified characterization gaps
Set the law aside for a moment. A seller’s ingredient name or purity percentage cannot establish every relevant quality attribute. FDA's reviewers called both forms of the substance "not well-characterized" chemically, partly because suppliers use inconsistent names for it [3]. They also flagged possible immune reactions, which can be stronger when a peptide is injected under the skin.
FDA identifies gaps in chemical characterization, impurities and aggregate information. A single purity percentage does not establish identity, sterility, stability or every relevant quality attribute. These are different questions from whether the substance has a published reference monograph.
Investigational access requires the applicable authorization
Investigational access requires the applicable regulatory and ethics oversight, beyond appearing in a registry [1]. As of this update, ClinicalTrials.gov lists one trial that gives MOTS-c to people [8].
- Design: phase 2a, randomized, double-blind, placebo-controlled.
- Who: adults 18 to 65 with prediabetes and overweight or obesity.
- Size: about 120 people planned.
- Where: one site, in China. No US site is listed.
- Status: recruiting; estimated primary completion is February 2027. A reporting date is not guaranteed.
Other ClinicalTrials.gov entries that mention MOTS-c measure the body's own levels; they don't give the peptide. If a trial interests you, a clinician can help you search the listings and judge whether you'd qualify.
What a prescriber can offer instead
MOTS-c was put forward to FDA for insulin resistance, obesity, osteoporosis and longevity, among other uses. FDA's own review notes that approved drugs already exist for weight reduction in obesity and for osteoporosis [3]. Those have labels. They have trials behind them, and pharmacies may fill them.
If a clinic or telehealth service offers you MOTS-c anyway, ask what the product is, which pharmacy made it, and under which FDA route. Those are the same questions behind every provider check on this site.
What would have to happen for the answer to change
Advisory recommendations are nonbinding. The current 503A regulation does not list MOTS-c; the pending OIRA notice does not publish final policy terms or establish a new exemption [11] [2]. A registry entry is separate from applicable investigational authorization.
The registry’s primary completion estimate is February 2027 and overall completion estimate is May 2028 [10]. Dates can change; they are neither a guaranteed publication date nor proof of a treatment benefit.
Athletes: banned at all times
WADA's 2026 Prohibited List names MOTS-c under S4.4.1, activators of AMP-activated protein kinase, in a class prohibited in and out of competition [9]. How testing works is covered in how long MOTS-c stays in your system.
The current NCT07505745 record lists 120 estimated participants, recruiting at a site in China, with no posted results. Structured primary outcomes are insulin sensitivity at 12 weeks and adverse events through 16 weeks. Its detailed narrative also names body weight and waist circumference, although those are absent from the structured outcome list. That reporting difference prevents a categorical claim that weight will not be measured [10].
Product eligibility, benefit and safety are separate questions. Read the MOTS-c fat-loss evidence and MOTS-c safety review before interpreting a clinic’s marketing.